Chicago Capital LLC increased its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) during the second quarter, according to the company’s most recent disclosure to the SEC. A decrease of 0.6%. The fund owned 5,810,468 shares of the biopharmaceutical company after selling 34,780 shares during the quarter. Dynavax Technologies makes up 3.4% of Chicago Capital LLC’s portfolio, making it the fifth-largest holding. As of the latest SEC filing, Chicago Capital LLC owns approximately 4.55% of Dynavax Technologies shares, worth $75,071,000.
Several other institutional investors have also recently modified their holdings in the business. Bank of America Corp DE grew its position in Dynavax Technologies by 811.6% during the first quarter. Bank of America Corp DE now owns 4,340,287 shares of the biopharmaceutical company’s stock valued at $42,578,000 after purchasing an additional 3,864,170 shares during the last quarter. State Street Corp lifted its position in Dynavax Technologies by 36.1% during the first quarter. State Street now owns 8,498,732 shares of the biopharmaceutical company’s shares valued at $92,126,000 after acquiring an additional 2,253,376 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Dynavax Technologies by 63.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,931,727 shares of the biopharmaceutical company’s stock valued at $28,759,000 after acquiring an additional 1,140,347 shares during the last quarter. Renaissance Technologies LLC grew its position in Dynavax Technologies by 64.3% in the first quarter. Renaissance Technologies LLC now owns 2,646,309 shares of the biopharmaceutical company’s stock valued at $25,960,000 after acquiring an additional 1,035,658 shares during the last quarter. Finally, Mizuho Markets Cayman LP purchased a new stake in shares of Dynavax Technologies during the first quarter valued at $7,425,000. Institutional investors hold 99.13% of the company’s shares.
Dynavax technology value for money
Nasdaq DVAX shares opened at $14.77 on Friday. The company’s 50-day moving average price is $14.20 and its 200-day moving average price is $12.44. Dynavax Technologies Co. has a one-year low of $9.42 and a one-year high of $15.12. The company has a market capitalization of $1.9 billion, a P/E ratio of 20.51, and a beta of 1.52. The company has a current ratio of 17.78, a quick ratio of 16.59, and a debt-to-equity ratio of 0.38.
Dynavax Technologies (NASDAQ:DVAX – Get Free Report ) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping consensus estimates of $0.09 by $0.12. Dynavax Technologies has a net profit margin of 24.08% and a return on equity of 19.91%. The company’s revenue for the quarter was $60.25 million, while analysts expected $51.03 million. Equities research analysts expect that Dynavax Technologies Co. will post -0.23 earnings per share for the current fiscal year.
Wall Street analysts forecast growth
Several analysts have commented on the stock. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Dynavax Technologies in a research note on Friday, August 4th. StockNews.com started coverage on shares of Dynavax Technologies in a report on Thursday, August 17th. They set a “hold” rating on the stock. Finally, JMP Securities raised their price target on shares of Dynavax Technologies from $24.00 to $25.00 and gave the company an “outperform” rating in a report on Friday, August 4th.
Check out our latest stock report on DVAX
Insider Trading
In related news, Chief Operating Officer David F. Novack sold 20,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares sold for an average price of $14.48, for a total value of $289,600.00. Following the sale, the COO now owns 3,187 shares of the company’s stock, valued at approximately $46,147.76. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which is available at this hyperlink. In related news, Chief Operating Officer David F. Novack sold 20,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares sold for an average price of $14.48, for a total value of $289,600.00. Following the sale, the COO now owns 3,187 shares of the company’s stock, valued at approximately $46,147.76. The transaction was disclosed in a document filed with the Securities and Exchange Commission, which is available at this hyperlink. Additionally, Director Andrew AF Hack sold 1,500,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares sold for an average price of $14.39, for a total transaction price of $21,585,000.00. Following the completion of the sale, the director now owns 915,000 shares in the company, valued at approximately $13,166,850. Disclosure information for this sale can be found here. In the last quarter, insiders sold 1,605,518 shares of company stock valued at $23,148,941. Insiders own 2.62% of the company’s shares.
About Dynavax Technology
(free report)
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine used to prevent infection caused by all known hepatitis B virus subtypes in those aged 18 years and older in the United States and Europe.
read more
This breaking news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Dynavax Technologies, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks that top analysts were quietly whispering to clients to buy before the pandemic hit… and Dynavax Technologies wasn’t on the list.
While analysts currently have a Buy rating on Dynavax Technologies, these five stocks are considered better buys by analysts with the highest ratings.
Check out five stocks here
Do you expect global energy demand to shrink? ! If not, then it’s time to take a look at how energy stocks play in your portfolio.
Get this free report